Form 4: Cyclo Therapeutics Director Vivien Wong Reports Stock and Option Transactions

Director Vivien Wong reports acquisition of common stock in lieu of cash compensation and grant of stock options.

Summary

• On June 3, 2024, Vivien Wong, a director of Cyclo Therapeutics, Inc., acquired 7,813 shares of common stock.
• These shares were received in lieu of cash compensation for the first quarter of 2024, as per the company's non-employee director compensation policy.
• The shares were valued at $1.28 each, based on the closing price on June 3, 2024.
• Following this transaction, Wong directly owns 16,631 shares of common stock.
• Wong also acquired options to purchase 15,562 shares of common stock at an exercise price of $1.28 on June 3, 2024.
• The options vest over a one-year period in equal quarterly installments and expire on June 3, 2034.
• After the transaction, Wong directly owns 15,562 derivative securities.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine disclosure of insider transactions. The director receiving stock in lieu of cash compensation could be seen as a positive, but it's not a major event.

Positives

• The acquisition of shares by a director can be seen as a positive sign, indicating confidence in the company's future.

Future Outlook

There is no specific future outlook provided in this document.

Industry Context

This filing is a routine disclosure of insider transactions, which is a common practice for publicly traded companies. It provides transparency into the actions of company directors and officers.

Stakeholder Impact

• Shareholders may view the director's stock acquisition as a sign of confidence in the company.
• The transaction has a minimal impact on employees, customers, suppliers, and creditors.

Key Dates